Nature's Sunshine delivered a quarter management itself called poor, and the numbers support that verdict. Adjusted earnings came in at $0.14 per share, down 61.1% from a year ago. Revenue fell 9.1% to $116.6 million, or 7% in constant currency. GAAP EPS was $0.11 versus $0.30. No consensus figure was available to frame a beat or miss. The more telling comparison is the company against itself. Constant-currency growth swung from +7% in Q1 and +4% in Q2 to a 7% decline in Q3, and full-year guidance was cut for a second consecutive quarter. That is the central story. What looked earlier in 2026 like a growth narrative built on Asia and digital has reversed on both fronts at once.

The weakness ran through the entire income statement. Gross margin slipped to 72.9% from 73.3% a year ago, and from 73.7% in Q2, which the company attributed mainly to currency. Volume incentives rose to 32.0% of sales from 30.7% because of promotional timing and market mix. SG&A fell to $42.3 million from $45.7 million, below the $45-47 million quarterly run-rate management had guided. Even so, it still rose as a share of a shrinking sales base, to 36.3%. Operating margin compressed to 4.5% from 7.0%. The bottom line took an outsized hit from taxes: a $3.5 million provision consumed roughly two-thirds of $5.4 million in pretax income. Cash generation also weakened. The release shows nine-month operating cash flow of $9.7 million versus $25.4 million a year earlier. The call analysis cites $10.8 million versus $18.5 million, apparently on a different period basis. Either way, the trend is clearly lower.

The call explained where the business broke. China sales plunged 52% in constant currency, after -20% in Q2 and +40% in Q1. Management now expects China to remain a headwind into 2027, a notable retreat from the short-term framing offered last quarter. The CEO said operational disruptions in China damaged the consultant leadership base more than anticipated. That matters more because the December 2025 buyout of the noncontrolling interest gave Nature's Sunshine full exposure to the market just as it deteriorated. Taiwan's consultant base has been shrinking for two years. North America fell 6% against earlier guidance for mid-to-high single-digit growth. Digital, the standout engine, posted its first-ever decline at -1%, after +47%, +42% and +26% in the prior three quarters. Management cited lapping TikTok and viral-product comparisons, plus AI agents eroding paid-search effectiveness.

There are genuine positives. Recurring revenue is deepening: digital auto-ship rose to 40% of digital sales from 30%, and social-commerce auto-ship reached 53% versus 9%. Japan kept growing, Eastern Europe rose 7%, and Europe overall edged up 1% in constant currency. The pipeline of catalysts is real but mostly back-end loaded:

• a Lunea women's health launch across Japan, Korea and Taiwan this month;
• a reimagined U.S. direct-selling program with a gut-health lineup and new compensation plan by mid-2027;
• an Osaka consultant base in 2027;
• a pending new Asian market launch;
• a more proactive M&A search under new CFO Ruth Perkins.

The company did walk away from one acquisition target after diligence exposed a shaky revenue profile. That shows discipline, but it also means no near-term inorganic offset.

The revised outlook calls for $460-470 million in sales and $44-48 million in adjusted EBITDA. That is down from $490-500 million and $48-52 million in August, and from $500-515 million and $50-54 million originally. The new sales range implies a decline versus 2025's $480.1 million. Against nine-month EBITDA of $37.0 million, the guide implies roughly $7-11 million in Q4, at or below Q3's depressed $11.1 million. Fourth-quarter gross margin is guided to the low-72% range. Management is not calling a bottom.

The market setup offers little cushion. Shares opened at $17.21 after the August report, already well below the 200-day moving average of $20.46. The company repurchased stock during Q3 at an average of $15.27, suggesting shares traded lower during the quarter. The balance sheet remains a real support: $89.4 million in cash, up from $82.5 million at the end of Q2, and zero debt. That gives management room to fund relaunches and buybacks without financial strain.

The bottom line is that Nature's Sunshine's problem has shifted from a single troubled market to a broad loss of momentum. China is collapsing, North America is soft, and the digital growth engine has stalled. Credibility has been dented by back-to-back guidance cuts. The improving auto-ship mix, cost control and a debt-free balance sheet keep the long-term story intact. But most of the identified catalysts arrive in 2027, leaving investors to absorb at least another weak quarter before any evidence of a turn.